Pilot Study of 89-Zr Panitumumab in Pancreas Cancer

Stanford University

Status and phase: Withdrawn; Phase 1

Conditions: Pancreas Cancer

Treatments: Drug: 89Zr-panitumumab

Study type: Interventional

Funder types: Other

Identifiers

NCT04833959

PANC0037 (Other Identifier)

NCI-2021-03447 (Other Identifier)

IRB-57641

Details and patient eligibility

About

The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed diagnosis of pancreatic cancer.

Exclusion criteria

• Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment.
• History of infusion reactions to monoclonal antibody therapies.
• Pregnant or breastfeeding.
• Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
• Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.
• Severe renal disease or anuria.
• Known hypersensitivity to deferoxamine or any of its components.

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

89Zr-Panitumumab

Experimental group

Description:

Subjects will be injected with 1 mCi (+/- 20%) of 89Zr-panitumumab followed by PET/CT imaging 4-7 days after study drug injection.

Treatment:

Drug: 89Zr-panitumumab